ResearcherUniversity of PittsburghActive in the last 2 years
Hussein H. Khachfe
Matched on ORCID iD 0000-0001-7537-9033; OpenAlex author ID A5010924091. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2023: 3 papers · 2024: 2 papers
Papers 5
- Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27595↗
- Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27856↗
- The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.hpb.2022.12.002↗
- No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.01.016↗
- Obesity Is Associated With Increased Risk for Adverse Postoperative Outcomes After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2022.11.050↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Amer H. Zureikat · 5 shared papers, 2023–2024 · strength 0.90
- Paper Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ducta… DOI 10.1002/jso.27595↗
- Paper Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. DOI 10.1002/jso.27856↗
- Paper Obesity Is Associated With Increased Risk for Adverse Postoperative Outcomes After Distal Pancreatectomy for Pancreatic… DOI 10.1016/j.jss.2022.11.050↗
- Samer S. AlMasri · 5 shared papers, 2023–2024 · strength 0.90
- Paper Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ducta… DOI 10.1002/jso.27595↗
- Paper Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. DOI 10.1002/jso.27856↗
- Paper Obesity Is Associated With Increased Risk for Adverse Postoperative Outcomes After Distal Pancreatectomy for Pancreatic… DOI 10.1016/j.jss.2022.11.050↗
- Alessandro Paniccia · 5 shared papers, 2023–2024 · strength 0.90
- Paper Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ducta… DOI 10.1002/jso.27595↗
- Paper Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. DOI 10.1002/jso.27856↗
- Paper Obesity Is Associated With Increased Risk for Adverse Postoperative Outcomes After Distal Pancreatectomy for Pancreatic… DOI 10.1016/j.jss.2022.11.050↗
- Ibrahim Nassour · 3 shared papers, 2023–2024 · strength 0.56
- Paper Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ducta… DOI 10.1002/jso.27595↗
- Paper Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. DOI 10.1002/jso.27856↗
- Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
- Aatur Dilip Singhi · 3 shared papers, 2023–2024 · strength 0.51
- Paper Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. DOI 10.1002/jso.27856↗
- Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
- Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
- Hao Liu · 2 shared papers, 2023 · strength 0.31
- Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
- Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
- Nathan Bahary · 2 shared papers, 2023 · strength 0.31
- Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
- Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
- Hao Liu · 1 shared paper, 2024 · strength 0.20
- Sowmya Narayanan · 1 shared paper, 2024 · strength 0.20
- Asmita Chopra · 1 shared paper, 2024 · strength 0.20
- Anthony Gebran · 1 shared paper, 2024 · strength 0.20
- Caroline J. Rieser · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.